Recent Updates
Recently added Catalysts

PET imaging

Phase 1

Triple Negative Breast Cancer | Unknown | Oncology |Lantheus Holdings, Inc.|Last Updated: Mar 27, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment30
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06586047Breast Cancer PSMA PETEARLY_PHASE1 RECRUITING 30Aug 29, 2024Dec 29, 2026Mar 27, 20261 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Lesion detection sensitivity analysis
4 weeks

Comparing the sensitivity of 18 F-DCFPyL-PET/CT and FDG PET/CT in metastatic lesion detection in triple-negative breast cancer patients.

Secondary Endpoints
Quantitative radiotracer uptake analysis
4 weeks
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeDIAGNOSTIC
Treatment Arms
ArmTypeDescription
PET Imaging of breast cancer patientsEXPERIMENTALTriple negative breast cancer patients will undergo FDG PET/CT and Pyl PET/Ct
Interventions
NameTypeDescription
PET imagingDIAGNOSTIC_TESTImaging with FDG PET/CT and Pyl PET/CT in triple negative breast cancer
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 90 Years
SexFEMALE
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Female \>= 18 years of age * Patients in distantly metastatic TNBC based on the initial diagnosis biopsy. * Patient should have FDG positive metastatic lesions on the initial PET/CT scan performed in this study to be further included. Exclusion Criteria: * Patients with know...

Countries:United States
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 24, 2026NCT06586047studyFirstPostDate: changed